Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market

The 3D printed medical prosthetics market consist of sales of 3D printed medical prosthetics devices and related services. 3D printing technology is used to create an artificial three dimensions’ physical object with the help of computer-aided design, and these prosthetics are intended to help patients with missing or defective body parts to restore normal functions. The global 3D printed prosthetics market is expected grow from $0.06 billion in 2020 to $0.07 billion in 2021 at a compound annual growth rate (CAGR) of 16.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.12 billion in 2025 at a CAGR of 14%. The 3D printed medical prosthetics market covered in this report is segmented by material into polypropylene, polyethylene, acrylics, polyurethane. The rising number of accidental injuries is driving the growth of the 3D printing prosthetic devices market. Accidental injuries can cause serious damage to a person, and these injuries can sometimes lead to amputation. In 2019, car crashes in the US resulted in the death of 38,800 people. According to a report from National Centre for Health Statistics, approximately 50,000 new amputation cases come up each year in the US. Increase in incidences of other medical conditions such as diabetes and vascular diseases is also leading to a rise in amputation cases, thus boosting the sales of 3D printing prosthetics. For instance, according to a report published in the American Journal of Managed Care, it was estimated that, globally, one patient leg is amputated in every 30 seconds and around 85% of these amputations were result of a diabetic foot ulcer. The delay in elective procedures attributing to the coronavirus outbreak is to act as a major factor to limit the growth of the 3D printed medical prosthetics market. Many countries and hospitals have diverted their healthcare resources to deal with COVID-19 patients. For instance, according to the Centers for Medicare & Medicaid Services (CMS) safety guidelines released in March 2020, all the elective and non-essential surgical, dental, and medical procedures are delayed in the USA during 2019 Novel Coronavirus (COVID-19) outbreak. Hence, the delays in surgical or elective procedures are projected to decline the demand for 3D printed medical prosthetics market in the near future. Companies in the 3D printing prosthetics market are focusing on development of waterproof prosthetic devices. The aim behind this innovation is to provide the user with an increased range of mobility, especially in athletics. In October 2020, Braskem, Americas leading producer of biopolymers has launched Braskem e-NABLE Chapter for Philanthropic Creation of 3D Printed Prosthetic Devices. Braskem was selected to be certified to produce the e-NABLE Phoenix V3 prosthetic hand as it is one of the most commonly produced e-NABLE prosthetic devices. The major players covered in the global 3d printed prosthetics market are 3D Systems corporation, EnvisionTEC, Stratasys Ltd., Bionicohand, YouBionic, UNYQ, Mecuris, LimbForge, Inc., Open Bionics, Protosthetics, Create Prosthetics, Bio3D Technologies, Laser GmbH, Prodways Group, 3T RPD Ltd., Photopolymerization, laser beam melting, Formlabs, Concept Laser, EOS GmbH Electro Optical Systems, Renishaw Plc, Groupe Gorge SA, Biomedical Modelling, Carbon Inc., Ottobock, Freedom innovation. The countries covered in the global 3D printed prosthetics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global 3D printed prosthetics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global 3D printed prosthetics market is segmented - 1) By Material: Polypropylene, Polyethylene, Acrylics, Polyurethane 2) By Type: Sockets, Limbs, Joints, Covers, Others 3) By End-User: Hospitals, Rehabilitation Centers, Prosthetic Clinics

The prosthetic heart valve devices and equipment market consists of sales of prosthetic heart valve devices and equipment. These devices that are implanted in the heart of patients who have valvular heart disease. The prosthetic heart valve helps in the reduction of discomfort due to a diseased valve in the heart and reduces the risk of mortality. Mechanical heart valves, transcatheter heart valves and tissue heart valves are a few examples of prosthetic heart valves. The global prosthetic heart valve devices and equipment market is expected to grow from $2.26 billion in 2020 to $2.36 billion in 2021 at a compound annual growth rate (CAGR) of 4.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.47 billion in 2025 at a CAGR of 10.1%. Rising prevalence of valvular heart disease has driven the need for transcathether aortic valve replacement (TAVR) procedures, thus driving the prosthetic heart valve devices and equipment market. TAVR is a minimally-invasive surgical procedure done to cure aortic sthenosis which is a valvular heart disease that affects the aortic valve of the heart. Aortic sthenosis affects the aortic valve by hardening it, thus not allowing blood to properly flow through it and TAVR is used to replace this defective aortic valve with a transcatheter valve. According to a report from The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry, volumes have grown every year. In 2019 TAVR passed all forms of surgical aortic valve replacement (SAVR) for the initial time. According to the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients, the annual size of TAVR has increased every year and in 2019, TAVR volume (72,991) passed all forms of SAVR (57,626). As the rate of occurrence of valvular heart diseases rise, the number of TAVR procedures done can be expected to increase which also increases the demand for transcatheter valves, thus driving the market going forward. Prosthetic heart valve devices have stringent procedures for approval which restrains the growth of the prosthetic heart valve devices and equipment market. According to the US food and drugs administration (FDA), randomized clinical trials are required for any medical device, in order to test for its safety standards. Randomized clinical trial is a clinical method of study that involves the separation of groups of patient subjects using random selection. This is done to compare different medicines and treatment methods in a fair manner with no room for bias and also to detect side-effects, if any. However, these random clinical trials take long periods of time. For example, Abbott Vascular Inc. filed an approval application for their mitraclip delivery system in 2010 and they received their approval for the same in 2019. Companies in this market are increasingly preferring polymer valves over traditional mechanical and bio-prosthetic valves/tissue valves. Polymer heart valves are prosthetic heart valves made of polymeric materials and have better functioning than tissue and mechanical heart valves. Mechanical heart valves come with a lifelong requirement of using blood-thinning medication to prevent blood clotting whereas bio-prosthetic heart valves comes with a short life span that needs several replacements and have a risk of valve degradation. Polymeric heart valves on the other hand supports better blood flow and reduces risk of blood clotting and therefore does not have the disadvantages of tissue and mechanical valves. Therefore, various companies are focusing on development of polymeric heart valve technologies, For instance, in October 2019, the California Institute of Technology and Foldax announced the development of the Tria heart valve that combines LifePolymer, an advanced biopolymer material, and a patented bio-inspired design to offer a heart valve able of serving for 15 years without calcification, risk of clotting, or damage to red blood cells. The prosthetic heart valve devices and equipment market is monitored by regulatory bodies such as FDA in the US and The Central Drugs Standard Control Organization (CDSCO). For instance, CDSCO issued a notice regarding the classification of the risk levels of different medical devices. Under this classification, prosthetic heart valves are considered as class "D" or high risk devices. Similarly, in order for manufacturers to produce and sell prosthetic valve devices in India, they need to sign forms MD-7 and MD-8 which come under the direct purview of the central government of India. Form MD-7 is used to register prosthetic valve manufacturers in India and form MD-8 is used by prosthetic valve manufacturers to apply for loans. Major players in the market are Boston Scientific, Edward life sciences, Medtronic, Livanova and Abbott. The countries covered in the global prosthetic heart valve devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global prosthetic heart valve devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global prosthetic heart valve devices and equipment market is segmented - 1) By Type: Transcatheter Heart Valve, Tissue Heart Valve,  Mechanical Heart Valve 2) By Application: Hospitals, Ambulatory Surgery Centres 3) By Product Type: Repair Products, Mitral Valve Repair Devices, Tricuspid Valve Repair Devices. 4) By Technology: Biological Valve, Decellularized Valve

The arthroscopy devices and equipment market consists of sales of arthroscopy devices and equipment and related services. Arthroscopy devices are used in arthroscopy procedures (a minimally invasive procedure) for the diagnosis and treatment of joint problems such as torn cartilage, ACL, and sports related injuries conducted on hip, knee, shoulder, spine, ankle, wrist, and elbow. The key products include arthroscopies, radiofrequency probes, patient positioning systems, fluid management systems, cannula, hand instruments, fixation devices, and accessories. The global arthroscopy devices and equipment market is expected to grow from $2.25 billion in 2020 to $2.52 billion in 2021 at a compound annual growth rate (CAGR) of 12%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.9 billion in 2025 at a CAGR of 3.6%. Rise in product recalls is one of the restraints for the arthroscopy treatment devices and equipment market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, the company baers all the cost of fixing the defective product and cost of replacement. This replacement cost for large number of products can go up to multi-million dollars, restraining the growth of the company and for the whole market as well. For example, in April 2019, Brainlab AG recalled spine and trauma 3-dimensional navigation due to inaccurate exposure that could lead to erroneous use.. The arthroscopy device and equipment industry is witnessing rise in mergers and acquisition activity. Major companies in the arthroscopy device market strategically acquired start-ups and mid-sized companies to broaden their products and services. For instance, in 2019, Smith & Nephew acquired Ceterix orthopedics in order to expand its product portfolio on NovoStitch Pro Meniscal Repair System, a knee repair device, and capitalize on the rising demand. Anika Therapeutics is in strategic partnerships with industry leaders such as DePuy Synthes, Mitek Sports Medicine, Medtronic, and Boehringer Ingelheim to develop new orthrobiologics. In December 2018, In2Bones Global, Inc. launched the U.S. commercial market release of the CoLink Afx ankle fracture system. The system is a combination of five plate issues that address traumatic fractures and osteotomies of the ankle. In June 2018, Medicines and Healthcare products Regulatory Agency (MRHA), a regulatory body for arthroscopic and orthopedic devices of the UK, sent an urgent field safety notice to Stryker Corporation, a medical and Orthopedics device manufacturer, initiating a lot-specific recall for the Stryker hip Products. The notice was sent as the implantation devices were either larger or smaller than the intended device. This impacted patient’s health by insufficient soft tissue tension, excessive stress in soft tissue, hip instability and risks associated with revision surgeries. To reduce incidences associated with these devices MRHA has sent an urgent field safety notice to take a corrective action by returning to supplier in order to conduct an investigation and correct the device. In 2018, Stryker Corporation acquired K2M Group Holdings, Inc. for $1.4 billion. This acquisition will strengthen and expand Stryker's offerings in the arthroscopy, minimally invasive spine portfolio and increase its capabilities in additive manufacturing. K2M Group Holdings, Inc., a company offering complex spine and minimally invasive solutions, designs, develops, and commercializes innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. The company was founded in 2004 and is headquartered in Leesburg, Virginia, USA. Major players in the market are Arthrex, Inc., Smith & Nephew, ConMed Corporation, Stryker and Medtronic. The countries covered in the global arthroscopy devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global arthroscopy devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global arthroscopy devices and equipment market is segmented - 1) By Product: Arthroscopes, Arthroscopy Shavers, Arthroscopy Fluid Management System, Arthroscopy Radiofrequency System, Arthroscopy Visualization System, Arthroscopy Implants 2) By Application: Knee Arthroscopy, Hip Arthroscopy, Spine Arthroscopy, Foot & Ankle Arthroscopy, Shoulder & Elbow Arthroscopy, Others 3) By End User: Hospitals, Ambulatory Care, Trauma Centers

The orthopedic prosthetics market consists of sales of orthopedic prosthetic devices. Orthopedic prosthetics are artificial devices used to replace a missing body part lost due to disease, trauma, surgical removal of body appendage, disabling illness or congenital conditions. Orthopedic prosthetic devices are segmented into upper and lower extremity prosthetics. Upper extremity prosthetics include hand, elbow, shoulder and lower extremity prosthetics include foot and ankle, knee, hip. The global orthopedic prosthetics market is expected to grow from $1.75 billion in 2020 to $1.95 billion in 2021 at a compound annual growth rate (CAGR) of 11.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.53 billion in 2025 at a CAGR of 6.7%. The orthopedic prosthetics market is being driven by an increasing number of trauma cases and accidental injuries. The trauma cases and accidental injuries are caused by various factors such as road accidents, sports injuries, other medical complications and work related accidents. Most of these injuries may require amputations and prosthetic devices to replace the lost body part. For instance, as of 2017 there are 2.1 million people living with limb loss in the USA and about 300-500 amputations were performed each day. Therefore, driving the demand for orthopedic prosthetics, thus growth in the orthopedic prosthetics market. The orthopedic prosthetics market is being restrained by entry barriers due to guidelines by the FDA's regulatory control over these devices based on the risks associated with them. These devices fall into the class III category as per the FDA, which includes devices involving high risk associated with the usage. Class III devices are required to undergo a premarket approval application (PMA), which is the FDA process of scientific evaluation for assessing the safety of these devices. Such stringent guidelines associated with these devices are creating an entry barrier and thus restraining the orthopedic prosthetics market. For instance, DePuy's hip prosthetic device was denied approval by the FDA after it was assessed as unsafe, thus creating an entry barrier and restraining the market. The companies in the orthopedic prosthetics market are witnessing the emergence of 3D printed orthopedic prosthetics. 3D printing is a process which involves a digital model being transformed into a three dimensional solid object. 3D printed orthopedic prosthetics are devices that are manufactured by the process of 3D printing. These devices have shorter lead times, lower costs and consistent quality. For instance, Zdravprint is a Russian company which is developing prosthetics for hand, elbow and shoulder using 3D printing technology. The orthopedic prosthetics market is regulated as per the guidelines by the food and drug administration (FDA). The FDA has subjected these devices under the class III category, which includes those devices involving a high risk associated with the usage. Class III devices are required to undergo a premarket approval application (PMA) before they can be used. PMA is the process followed by the FDA for scientific evaluation, to assess the safety of the devices. If a PMA application is found to be lacking valid clinical assessment and correct scientific reasoning, it impacts the FDA's approval and prevents the prosthetic device from being released into the market. In June 2019, Smith & Nephew acquired orthopedic joint reconstruction business from Brainlab for an undisclosed amount. With this acquisition the company expands its business of shoulder and wrist implants. The Brainlab orthopaedic joint reconstruction business provides surgeons with digital workflow tools, from pre-operative planning to intraoperative navigation to postoperative evaluation and sharing. Major players in the market are Otto Bock HealthCare GmbH, Blatchford Ltd, Zimmer Biomet Inc., DePuy Synthes, Stryker Corp. The countries covered in the global orthopedic prosthetics market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global orthopedic prosthetics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global orthopedic prosthetics market is segmented - 1) By Product Type: Upper Extremity Prosthetics, Lower Extremity Prosthetics, Sockets, Other Products 2) By End Users: Hospitals, Prosthetic Clinics, Rehabilitation Center, Others 3) By Technology: Conventional Orthopedic Prosthetics, Electric-powered Orthopedic Prosthetics, Hybrid Orthopedic Prosthetics

The voice prosthesis devices and equipment market consist of sales of voice prosthesis devices and equipment and related services. Voice prosthesis devices and equipment are artificial devices that provide the capability to speak in patients who have undergone laryngectomy (removal of larynx). These devices are placed in the tracheo-esophageal puncture, an opening created between trachea (wind pipe) and esophagus (food pipe) by surgeons. The global voice prosthesis devices and equipment market is expected to grow from $0.45 billion in 2020 to $0.5 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.56 billion in 2025 at a CAGR of 2.9%. The voice prosthesis device and equipment market is driven by an increasing number of cases of larynx cancer. Larynx cancer is a disease in which malignant cancer cells form tissue in the larynx and cause sore throat and ear pain. According to the WHO, there were 99840 deaths reported in 2020 due to Larynx cancer. High equipment cost of voice prosthesis devices and equipment hampers the voice prosthesis devices and equipment market growth. High equipment costs refer to the replacement of prosthesis devices and equipment after a certain period of time. For instance, JAMA Otolaryngol Head Neck Surgery center found that average life of the prosthesis devices and equipment is 3-6 months after which the device has to be changed. Technological advancements of voice prosthesis devices and equipment have increased various properties of devices including, lifetime of the device, simple and easy maintenance by patients, and comfortable outpatient replacements. For instance, the Indwelling prostheses are designed to meet the criteria of low air resistance and optimal retention in the tracheoesophageal wall, these prostheses devices and equipment have become the valve of choice with the success rate of 40-90% having very good voice quality. Medical devices including ENT surgical devices enter the market through FDA 510(K) premarket clearance pathway, As announced by FDA in November 2018 this regulation is set to undergo changes in which more efficient medical devices clearance process to introduce a new generation of safety, technology, and capabilities in medical devices. The EU’s Medical Device Regulation (MDR) came into force in 2020. The future of ENT devices is likely to be impacted by both modernization of FDA 510(k) pathway and forthcoming enforcement of new EU MDR regulations. On January 11 2018, Atos acquired Heimomed Heinze GmbH & Co. KG – a medical technology company operating in Germany and Austria. This acquisition strengths the Atos groups presence in Germany and Austria. In conjunction with the acquisition, Atos’ customers will also gain access to Heimomed’s high-quality tracheostomy products. Major players in the market are Atos Medical, Andreas Fahl Medizintechnik–Vertrieb, Servona, Acclarent, Inc. (A Subsidiary of Johnson & Johnson) and Karl Storz Gmbh & Co. Kg. The countries covered in the global voice prosthesis devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global voice prosthesis devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global voice prosthesis devices and equipment market is segmented - 1) By Device Type: Indwelling Voice Prosthesis Devices, Non-Indwelling Voice Prosthesis Devices 2) By Product Type: Soft Valve Assembly, Hard Valve Assembly, Others 3) By Valve Type: Blom-Singer Valve, Provox Valve, Groningen Valve 4) By Material: Silicone Rubber, Silicone, Fluoroplastic, Silver Oxide, Others 5) By End User: Hospitals, Ambulatory Surgical Centers, Clinics

The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy and targeted therapy. The global prostate cancer drugs market is expected to grow from $3.65 billion in 2020 to $3.87 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.31 billion in 2025 at a CAGR of 8.2%. The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 703 million people aged 65 or above globally, accounting for 13% of the global population in 2019. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40. Recurrent/non-responsive prostate cancer is major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of the cancer after an initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). The cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment. The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, in February 2018, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI® (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer. The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for approval of new drugs and lays down regulations related to treatment of prostate cancer. In February 2018, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market. In 2018, Novartis acquired Endocyte for $2.1 billion. This acquisition will help Novartis to develop expands its radiotherapy capabilities for the treatment of prostate cancer. Endocyte is a biopharmaceutical company involved in developing target therapies for the personalized treatment of cancer. It was founded in 1996 and headquartered in Indiana, the USA. Major players in the market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG. The countries covered in the global prostate cancer drugs market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global prostate cancer drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global prostate cancer drugs market is segmented - 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy 3) By End User: Hospitals, Clinics, Others

The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50. The global drugs for benign prostatic hypertrophy market is expected to grow from $4.15 billion in 2020 to $4.79 billion in 2021 at a compound annual growth rate (CAGR) of 15.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.3 billion in 2025 at a CAGR of 7.1%. The rising male geriatric population globally is driving the market for benign prostatic hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health(NIH), benign prostatic hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years. Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of benign prostatic hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume benign prostatic hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat benign prostatic hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA). Combination drugs are increasingly being used in the treatment of benign prostatic hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of benign prostatic hypertrophy. Benign prostatic hypertrophy drugs manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate safety and efficacy of drugs using clinical trials data which will be assessed by competent authorities before authorizing for sale. Major players in the market are Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC. The global drugs for benign prostatic hypertrophy market is segmented - 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others 2) By End User: Hospital Pharmacies, Retail Pharmacies, Others 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Anti-Asthmatic and COPD Drugs Definition

The anti-asthmatics and COPD drugs market consists of sales of anti-asthmatics and COPD drugs by entities (organizations, sole traders and partnerships) that manufacture anti-asthmatics and COPD drugs which are used to prevent and treat asthma and chronic obstructive pulmonary disease (COPD). The anti-asthmatics and COPD drug industry includes establishments that manufacture anti-asthmatics and COPD drugs such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs. Asthma is a condition that causes the airways in the body to narrow and swell and generate extra mucus. This can make breathing difficult, resulting in coughing, wheezing on exhalation and shortness of breath. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction in the lungs. Breathing difficulties, cough, mucus production and wheezing are all symptoms.